Literature DB >> 27060620

Hafnium-doped hydroxyapatite nanoparticles with ionizing radiation for lung cancer treatment.

Min-Hua Chen1, Nobutaka Hanagata2, Toshiyuki Ikoma3, Jian-Yuan Huang4, Keng-Yuan Li4, Chun-Pin Lin5, Feng-Huei Lin6.   

Abstract

UNLABELLED: Recently, photodynamic therapy (PDT) is one of the new clinical options by generating cytotoxic reactive oxygen species (ROS) to kill cancer cells. However, the optical approach of PDT is limited by tissue penetration depth of visible light. In this study, we propose that a ROS-enhanced nanoparticle, hafnium-doped hydroxyapatite (Hf:HAp), which is a material to yield large quantities of ROS inside the cells when the nanoparticles are bombarded with high penetrating power of ionizing radiation. Hf:HAp nanoparticles are generated by wet chemical precipitation with total doping concentration of 15mol% Hf(4+) relative to Ca(2+) in HAp host material. The results show that the HAp particles could be successfully doped with Hf ions, resulted in the formation of nano-sized rod-like shape and with pH-dependent solubility. The impact of ionizing radiation on Hf:HAp nanoparticles is assessed by using in-vitro and in-vivo model using A549 cell line. The 2',7'-dichlorofluorescein diacetate (DCFH-DA) results reveal that after being exposed to gamma rays, Hf:HAp could significantly lead to the formation of ROS in cells. Both cell viability (WST-1) and cytotoxicity (LDH) assay show the consistent results that A549 lung cancer cell lines are damaged with changes in the cells' ROS level. The in-vivo studies further demonstrate that the tumor growth is inhibited owing to the cells apoptosis when Hf:HAp nanoparticles are bombarded with ionizing radiation. This finding offer a new therapeutic method of interacting with ionizing radiation and demonstrate the potential of Hf:HAp nanoparticles in tumor treatment, such as being used in a palliative treatment after lung surgical procedure. STATEMENT OF SIGNIFICANCE: Photodynamic therapy (PDT) is one of the new clinical options by generating cytotoxic reactive oxygen species (ROS) to kill cancer cells. Unfortunately, the approach of PDT is usually limited to the treatment of systemic disease and deeper tumor, due to the limited tissue penetration depth of visible light (620-690nm). Here we report a ROS-enhanced nanoparticle, hafnium-doped hydroxyapatite (Hf:HAp), which can trigger ROS when particles are irradiated with high penetrating power of ionizing radiation. The present study provides quantitative data relating ROS generation and the therapeutic effect of Hf:HAp nanoparticles in lung cancer cells. As such, this material has opened an innovative window for deeper tumor and systemic disease treatment.
Copyright © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Doping; Hafnium; Hydroxyapatite; Ionizing radiation; ROS; pH-dependent solubility

Mesh:

Substances:

Year:  2016        PMID: 27060620     DOI: 10.1016/j.actbio.2016.04.004

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  13 in total

1.  One Ion to Rule Them All: Combined Antibacterial, Osteoinductive and Anticancer Properties of Selenite-Incorporated Hydroxyapatite.

Authors:  Vuk Uskoković; Maheshwar Adiraj Iyer; Victoria M Wu
Journal:  J Mater Chem B       Date:  2017-01-23       Impact factor: 6.331

2.  Magnetic and pH dual-responsive mesoporous silica nanocomposites for effective and low-toxic photodynamic therapy.

Authors:  Jieqiong Zhan; Zhiqiang Ma; Dan Wang; Xinfang Li; Xiangui Li; Lijing Le; Anfeng Kang; Pengwei Hu; Lan She; Feng Yang
Journal:  Int J Nanomedicine       Date:  2017-04-10

3.  Ubidecarenone-Loaded Nanostructured Lipid Carrier (UB-NLC): Percutaneous Penetration and Protective Effects Against Hydrogen Peroxide-Induced Oxidative Stress on HaCaT Cells.

Authors:  Jianmin Wang; Huiyun Wang; Qiang Xia
Journal:  Int J Mol Sci       Date:  2018-06-25       Impact factor: 5.923

Review 4.  Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.

Authors:  Jing Jin; Qijie Zhao
Journal:  J Nanobiotechnology       Date:  2020-05-14       Impact factor: 10.435

5.  The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors.

Authors:  Hongfeng Wu; Zhongtao Li; Jiaoqing Tang; Xiao Yang; Yong Zhou; Bo Guo; Lin Wang; Xiangdong Zhu; Chongqi Tu; Xingdong Zhang
Journal:  Int J Nanomedicine       Date:  2019-02-15

Review 6.  Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma.

Authors:  Yandong Xie; Yuhan Han; Xuefeng Zhang; Hongwei Ma; Linfeng Li; Rutong Yu; Hongmei Liu
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

Review 7.  Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells.

Authors:  Yan Liu; Pengcheng Zhang; Feifei Li; Xiaodong Jin; Jin Li; Weiqiang Chen; Qiang Li
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

Review 8.  Cationic Substitutions in Hydroxyapatite: Current Status of the Derived Biofunctional Effects and Their In Vitro Interrogation Methods.

Authors:  Teddy Tite; Adrian-Claudiu Popa; Liliana Marinela Balescu; Iuliana Maria Bogdan; Iuliana Pasuk; José M F Ferreira; George E Stan
Journal:  Materials (Basel)       Date:  2018-10-24       Impact factor: 3.623

Review 9.  Chemical Mechanisms of Nanoparticle Radiosensitization and Radioprotection: A Review of Structure-Function Relationships Influencing Reactive Oxygen Species.

Authors:  Douglas Howard; Sonia Sebastian; Quy Van-Chanh Le; Benjamin Thierry; Ivan Kempson
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

Review 10.  An Up-to-Date Review of Natural Nanoparticles for Cancer Management.

Authors:  Daniel Ion; Adelina-Gabriela Niculescu; Dan Nicolae Păduraru; Octavian Andronic; Florentina Mușat; Alexandru Mihai Grumezescu; Alexandra Bolocan
Journal:  Pharmaceutics       Date:  2021-12-22       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.